Flares Impact Quality of Life and Disease Control in Moderate Atopic Dermatitis: Real-World Insights
SKIN The Journal of Cutaneous Medicine · 14.07.2026 · 10 (4) · s793
DOI: 10.25251/8wd9rm14 ↗Kurz gefasst
Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 14.07.2026. Verfasst von Justin Love und 8 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Atopic dermatitis (AD) is characterized by recurrent flares, often managed reactively with topicals. Flares negatively affect quality of life (QoL), perception of disease control, sleep, and work productivity. This study aimed to assess the impact of flares on QoL in AD and explore the role of systemic therapy in flare prevention, acknowledging that such treatments are generally reserved for severe cases and less often prescribed for moderate AD.
Methods
Data were drawn from the Adelphi AD Disease Specific Programme™, a cross-sectional, real-world study (February 2021 to February 2022). Advanced Practice Providers reported flare status, severity, and treatment regimens. Patients aged ≥18 years with a history of moderate-to-severe AD completed the Dermatology Life Quality Index (DLQI), Patient-Oriented Eczema Measure (POEM), and Recap of Atopic Eczema (RECAP).
Results
A total of 625 patients with AD who reported experiencing flares were included (mean age 41.6 years; 56% female); among these, 41% patients were “currently flaring”. Among patients experiencing flares, 85% had moderate-to-severe AD, compared with 35% of patients who were not experiencing flares. In the current episode of flaring, 63% of patients experienced moderate flares, while 22% experienced severe flares. Flares were reported in 41% of patients receiving systemic therapy and 57% of those not receiving systemic therapy. Patients experiencing the current episode of flaring were treated with systemic therapy (41%), systemics plus topicals (37%), or topicals alone (38%), with a small proportion not receiving any current therapy (11%). Among patients with moderate AD, mean QoL scores were 6.7 versus 4.8 for DLQI, 9.2 versus 5.7 for POEM, and 10.9 versus 5.6 for RECAP (flaring vs nonflaring). Among patients with moderate AD, 31% of those currently flaring had a RECAP score
Zitieren
APA
Love, J., Miller, L., Silva, J., Dawson, Z., Pierce, E., Marwaha, S., Anderson, P., Piercy, J., & Young, M. (2026). Flares Impact Quality of Life and Disease Control in Moderate Atopic Dermatitis: Real-World Insights. SKIN The Journal of Cutaneous Medicine, 10(4), s793. https://doi.org/10.25251/8wd9rm14
Vancouver
Love J, Miller L, Silva J, Dawson Z, Pierce E, Marwaha S, et al. Flares Impact Quality of Life and Disease Control in Moderate Atopic Dermatitis: Real-World Insights. SKIN The Journal of Cutaneous Medicine. 2026;10(4):s793. doi:10.25251/8wd9rm14
BibTeX
@article{Love2026,
author = {Love, Justin and Miller, Lauren and Silva, Jennifer and Dawson, Zach and Pierce, Evangeline and Marwaha, Simran and Anderson, Peter and Piercy, James and Young, Melodie},
title = {Flares Impact Quality of Life and Disease Control in Moderate Atopic Dermatitis: Real-World Insights},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2026},
volume = {10},
number = {4},
pages = {s793},
doi = {10.25251/8wd9rm14}
}
EUVIMED